Skip to main content
logo
PharmaCorp Rx Inc. (TSXV:PCRX)
Canada flag Canada · Delayed Price · Currency is CAD
0.5000
0.00 (0.00%)
At close: Jul 31, 2026

PharmaCorp Rx Cash Flow Statement

Millions CAD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22
Net Income
-1.55-1.42-1.05-0.47-0.52
Depreciation & Amortization
1.110.940.29--
Stock-Based Compensation
-0.410.28-0.39
Other Adjustments
-0.04-0.04-0.11--
Changes in Other Operating Activities
-0.772.130.71-0.05-
Operating Cash Flow
-0.792.010.12-0.52-0.12
Operating Cash Flow Growth
-1505.50%---

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22
Capital Expenditures
-0.15-0.09-0.01--
Cash Acquisitions
--12.61-16.86--
Other Investing Activities
--1.02---
Investing Cash Flow
-13.79-13.72-16.86--

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22
Long-Term Debt Issued
-3.16---
Long-Term Debt Repaid
-0.21-0.18-0.06--
Net Long-Term Debt Issued (Repaid)
-0.212.98-0.06--
Issuance of Common Stock
-21.4427.490.032
Net Common Stock Issued (Repurchased)
-21.4427.490.032
Other Financing Activities
-0.160.29-0.05--0.13
Financing Cash Flow
25.0324.7127.380.031.87

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22
Net Cash Flow
10.441310.64-0.491.75

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22
Free Cash Flow
-0.941.920.12-0.52-0.12
Free Cash Flow Growth
-1525.00%---
FCF Margin
-3.90%9.18%2.04%--
Free Cash Flow Per Share
-0.010.020.00-0.01-0.00
Levered Free Cash Flow
-1.654.47-0.08-0.520
Unlevered Free Cash Flow
-1.640.55-0.65-0.630